Effects of a pro-resolving drug in COVID-19: preclinical studies to a randomized, placebo-controlled, phase Ib/IIa trial in hospitalized patients.
Almeida PRJ, Periard AM, Tana FL, Avila RE, Milhorato LB, Alcantara KMM, Resende CB, Serufo AV, Santos FR, Teixeira DC, Queiroz-Junior CM, Fonseca TCM, Silva BLV, Costa VV, Souza RP, Perretti M, Jonassen TEN, Teixeira MM.
Almeida PRJ, et al. Among authors: serufo av.
Br J Pharmacol. 2024 Dec;181(23):4750-4765. doi: 10.1111/bph.17322. Epub 2024 Aug 19.
Br J Pharmacol. 2024.
PMID: 39159951
Clinical Trial.